Materialise stock breaks through its 6.70 € support level and plummets 23.5%
The Belgian medical and industrial 3D printing group suffers a severe market sanction on the very day of its third quarter results publication. The market appears to be focusing more on profitability than on revenue growth.
Adjusted EBIT margin reduced to 3.7% despite sales increase
Materialise loses 23.38% to 5.90 €, compared to 7.70 € at the previous close, and records a decline of 14.79% over one week. Third quarter results, published this Wednesday, show revenue up 2.1% and gross margin rising to 57.7%, compared to 56.8% a year earlier.
However, research and development, commercial and administrative expenses increased by 7.8%, including 11.9% for research alone, resulting in adjusted EBIT margin falling to 3.7%, compared to 4.4% in the third quarter of 2025.
The group confirmed its two annual targets, including a revenue range of 273 to 283 M€ for 2026. Net cash has increased by 11.67 M€ since the end of 2025.
The 6.70 € support level broken through, the 200-day moving average at 5.60 € in sight
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The stock broke through its lowest level of the past 30 trading sessions during the session, at 6.70 €, which has now become a resistance level. It is now trading 20.27% below its 20-day moving average and 13.87% below its 50-day moving average. Only the 200-day moving average, at 5.60 €, remains below the current price, with a gap of 5.36%.
The RSI at 32 is close to the oversold zone. The next support level is at 4.44 €. Despite this decline, the stock retains a gain of 6.14% over three months and 16.41% over one year.
Related
SectorDispositifs médicaux et optique›Dispositifs médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: T3 2026
Key reported figures
Revenue: 67,7 millions d'euros
Quarterly revenue: 67,7 millions d'euros
Revenue growth: 2,1 %
EBITDA: 6,9 millions d'euros
EBITDA margin: 10,2 %
Net income: 1,4 millions d'euros
Free cash flow: 11,4 millions d'euros
-82,5 millions d'euros
Guidance from the release
« As a result, we are reconfirming our full-year 2026 revenue guidance of 273,000 to 283,000 kEUR » ; « We are also reaffirming the full-year Adjusted EBIT guidance that we increased in August »
Risks mentioned
Negatieve impact van recente desinvesteringen van RapidFit en Eyewear moet volledig worden gecompenseerd
Daling van gecorrigeerde EBIT-marge van 4,4% naar 3,7% jaar-op-jaar
Toename R&D-investeringen en eenmalige kosten drukken op rentabiliteit ondanks topline groei
Opportunities identified
Materialise Medical segment behaalt groei met dubbele cijfers
Materialise Manufacturing toont hernieuwde omzetgroei in focusmarkten luchtvaart en defensie na desinvesteringen
Sterke operationele kasstroom ondersteunt verdere investeringen in innovatie
Outlook / guidance
Expected revenue: 278 millions d'euros
Management commentary: « we are reconfirming our full-year 2026 revenue guidance of 273,000 to 283,000 kEUR, fully absorbing the unfavorable revenue impact of the recent RapidFit and Eyewear divestitures »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
